As of November 10, 2026, Climb Bio, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 3, 2026 to July 1, 2026 (Form 8-K, July 1, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Climb Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Climb Bio, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-03 to 2026-07-01. Every row below is cited to the filing it comes from, and this page adds each new change as Climb Bio, Inc. files it.
Also on the record for Climb Bio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 9, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 33% of the class | 5%+ stakes | Source |
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 15% of the class | 5%+ stakes | Source |
| October 28, 2026 | Stake report, Schedule 13G, by Deerfield Mgmt, L.P. | 5.25% of the class | 5%+ stakes | Source |
| October 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by MPM BioImpact LLC | — | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G, by FMR LLC | 11.9% of the class | 5%+ stakes | Source |
| July 7, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 33% of the class | 5%+ stakes | Source |
| May 4, 2026 | Form D, private offering | $110.08M sold | Form D page | Source |
| April 29, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 33% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by MPM BioImpact LLC | 5.6% of the class | 5%+ stakes | Source |
| December 15, 2025 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 33% of the class | 5%+ stakes | Source |
| October 16, 2025 | Stake report, Schedule 13D/A, by AI ETI LLC | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Climb Bio, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Climb Bio, Inc. and the records around it.
Climb Bio, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Company profile and every filing May 2026
- Form D filing May 2026
- Who owns it
Companies that share a holder
- Pontifax VI G.P. L.P. also filed stake reports on 3 other companies: Agomab Therapeutics NV (Apr 2026), Keros Therapeutics, Inc. (Oct 2025), LB Pharmaceuticals Inc (Sep 2025)
- MPM BioImpact LLC also filed stake reports on 4 other companies: Context Therapeutics Inc. (Aug 2026), DBV TECHNOLOGIES S.A. (Aug 2026), Forte Biosciences, Inc. (May 2026)
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026), BiomX Inc. (Jun 2026)
Watch Climb Bio, Inc.
Get an email when Climb Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Climb Bio, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Climb Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Climb Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-01 | Reported | not named in the filing | 8-K, 2026-07-01 | ||
| 2026-04-03 | Reported | not named in the filing | 8-K, 2026-04-03 |
New leaders reset buying decisions — get the Full Report on Climb Bio, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Climb Bio, Inc. (free up to 3)
Find people with the same kind of experience as the senior executive at Climb Bio, Inc., with the record behind each one.
Find candidates like senior executive at Climb Bio, Inc.Every change, in the filing's words
Reported
On June 29, 2026, Andrew Levin notified the board of directors (the "Board") of Climb Bio, Inc. (the "Company") of his resignation as a member of the Board, effective immediately.
- Election of New Director Also on June 29, 2026, upon the recommendation of the nominating and corporate governance committee of the Board, Breanna O'Reilly, Ph.D., was elected as a member of the Board, effective immediately.
- Dr. O'Reilly was elected to serve with a term expiring at the Company's 2027 annual meeting of stockholders and thereafter until her successor has been duly appointed and qualified or until her earlier death, resignation or removal.
- Dr. O'Reilly will also be entitled to receive (i) annual cash retainers in the amount of $40,000 for her service as a director and (ii) annual equity grants in accordance with the Company's non-employee director compensation policy.
Reported
On April 1, 2026, Climb Bio, Inc. (the "Company") and Cindy Driscoll, its Senior Vice President, Finance and principal accounting officer, mutually agreed that Ms. Driscoll would separate from the Company, effective April 30, 2026 (the "Separation Date").
- Appointment of Principal Accounting Officer As a result of Ms. Driscoll's separation, Dr. Altschuller, the Company's Chief Financial Officer and principal financial officer, will also serve as the Company's principal accounting officer, effective as of the Separation Date.
- Susan Altschuller, Ph.D., MBA, 44, has served as the Company's Chief Financial Officer since October 2025.
- She most recently served as Chief Financial Officer of Dragonfly Therapeutics, Inc., a private biotechnology company, from August 2024 to December 2024.
- Prior to that, she served as the Chief Financial Officer of Cerevel Therapeutics, Inc., or Cerevel, a publicly traded clinical-stage biopharmaceutical company, from May 2023 until its acquisition by AbbVie Inc. in August 2024.
- Prior to joining Cerevel, Dr. Altschuller was Chief Financial Officer of ImmunoGen, Inc., or ImmunoGen, a publicly traded biopharmaceutical company, from July 2020 to March 2023.
- Before ImmunoGen, Dr. Altschuller worked at Alexion Pharmaceuticals, Inc., a global biopharmaceutical company, where she served as Head of Enterprise Finance from April 2020 to July 2020 and Head of Investor Relations from January 2018 to April 2020.
Climb Bio, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Climb Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.